Diode Laser and Photodynamic Therapy Vs. Ciclopirox.

Sponsor
Universidad Complutense de Madrid (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05809297
Collaborator
(none)
26
2
21

Study Details

Study Description

Brief Summary

The main objective of this study is to compare the efficacy of treatment of onychomycosis by:

diode laser combined with photodynamic therapy, and topical treatment with Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer.

The study is a low-intervention, randomised controlled clinical trial. Patient recruitment will be done by including in the sample those patients who have diagnostic confirmation of onychomycosis in the Chiropodology and Surgery Service of the University Podiatry Clinic of the Complutense University of Madrid. Participants in the trial will be assigned with equal probability to each treatment arm, according to their consecutive inclusion in the study. Subsequently, treatment assignment will be determined by a random code. The treatment used will be evident to both the participant and the podiatrist responsible for the intervention.

Visits will be made every 7 days at the start of treatment and for 9 weeks in group 1 (treatment with laser and photodynamic therapy), and monthly visits in group 2 (treatment with ciclopirox nail polish) during the 12 months of follow-up. Regardless of the follow-up week at which healing occurs, all patients will be reviewed at 3, 6, 9 and 12 months after the first visit.

Condition or Disease Intervention/Treatment Phase
  • Device: Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®
  • Drug: Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer
Phase 4

Detailed Description

Visits will be made every 7 days at the start of treatment and for 9 weeks in group 1 (treatment with laser and photodynamic therapy), and monthly visits in group 2 (treatment with ciclopirox nail polish) during the 12 months of follow-up. Regardless of the follow-up week at which healing occurs, all patients will be reviewed at 3, 6, 9 and 12 months after the first visit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Diode Laser and Photodynamic Therapy Versus Ciclopirox Hydroxypropyl Chitosan. Randomised Controlled Clinical Trial.
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo® (MEDENCY)

According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.

Device: Diode laser combined with photodynamic-red laser therapy by RapidoPodia Laser Diodo®
According to the manufacturer's recommendations, the treatment will be carried out in consultation in 8 sessions by a specialised podiatrist.
Other Names:
  • Laser
  • Active Comparator: Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer

    The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.

    Drug: Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer
    The application of Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer will be performed at home by the patient once a day.
    Other Names:
  • Control
  • Outcome Measures

    Primary Outcome Measures

    1. Efficacy of treatment of onychomycosis with diode laser combined with photodynamic therapy versus Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer. [12 months]

      Clinical cure (yes/no).

    2. Efficacy of treatment of onychomycosis with diode laser combined with photodynamic therapy versus Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer. [12 months]

      Mycological cure (yes/no)

    3. Efficacy of treatment of onychomycosis with diode laser combined with photodynamic therapy versus Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer. [12 months]

      Complete cure (yes/no)

    Secondary Outcome Measures

    1. To determine whether 8 sessions of diode laser treatment combined with photodynamic therapy, at different wavelengths, over a period of nine weeks, is sufficient to achieve clinical cure of onychomycosis. [12 months]

      Clinical cure (yes/no)

    2. To determine whether 8 sessions of diode laser treatment combined with photodynamic therapy, at different wavelengths, over a period of nine weeks, is sufficient to achieve, mycological cure of onychomycosis. [12 months]

      Mycological cure (yes/no).

    3. To determine whether 8 sessions of diode laser treatment combined with photodynamic therapy, at different wavelengths, over a period of nine weeks, is sufficient to achieve complete cure of onychomycosis. [12 months]

      Complete cure (yes/no).

    4. To analyse the influence of the type of onychomycosis on the response to treatment. [12 months]

      Onychomycosis clasification (ODL, total dystrophic, superficial)

    5. To analyse the influence of the causal fungal agent on the response to treatment. [12 months]

      Causal fungal agent (dermatophyte, mould or yeast)

    6. To analyse the influence of the degree of severity of onychomycosis on the response to treatment. [12 months]

      Onychomycosis severity index (OSI)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients diagnosed with toenail onychomycosis with positive microbiological culture/PCR.

    • Patients over 18 years of age.

    Exclusion Criteria:
    • Patients who have received topical or systemic antifungal treatment in the previous month.

    • Pregnancy or lactation.

    • Patients with peripheral vascular disease.

    • Patients with an immune system disorder or undergoing treatment with immunosuppressants.

    • Patients with peripheral or central neuropathy.

    • Patients with a coagulation disorder.

    • Patients with Raynaud's disease or with any alteration in the perception of cold or heat.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Universidad Complutense de Madrid

    Investigators

    • Principal Investigator: Francisco Javier Álvaro Afonso, Complutense University of Madrid

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    FRANCISCO JAVIER ALVARO AFONSO, Principal Investigator, Universidad Complutense de Madrid
    ClinicalTrials.gov Identifier:
    NCT05809297
    Other Study ID Numbers:
    • Nº EudraCT 2022-003913-12
    First Posted:
    Apr 12, 2023
    Last Update Posted:
    Apr 12, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by FRANCISCO JAVIER ALVARO AFONSO, Principal Investigator, Universidad Complutense de Madrid
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 12, 2023